GoodRx (NASDAQ:GDRX) Trading 5.8% Higher – Still a Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX) was up 5.8% during mid-day trading on Friday . The stock traded as high as $4.54 and last traded at $4.53. Approximately 660,285 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 1,087,214 shares. The stock had previously closed at $4.28.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. KeyCorp dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday. Barclays cut their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Morgan Stanley decreased their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Citigroup cut their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday. Finally, Mizuho initiated coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target on the stock. Five investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.38.

GoodRx Stock Performance

The stock has a market cap of $1.73 billion, a PE ratio of -151.67, a P/E/G ratio of 3.43 and a beta of 1.27. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The stock has a 50-day simple moving average of $4.72 and a 200-day simple moving average of $6.56.

Institutional Trading of GoodRx

Institutional investors and hedge funds have recently bought and sold shares of the business. Fortem Financial Group LLC purchased a new stake in GoodRx during the third quarter worth approximately $772,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of GoodRx by 5.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock valued at $3,332,000 after acquiring an additional 26,262 shares in the last quarter. Barclays PLC boosted its position in GoodRx by 1,316.1% during the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after purchasing an additional 130,219 shares during the period. Raymond James & Associates increased its holdings in GoodRx by 212.6% in the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock valued at $2,734,000 after purchasing an additional 267,951 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd raised its position in GoodRx by 260.7% in the third quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock valued at $308,000 after purchasing an additional 32,104 shares during the period. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.